论文部分内容阅读
用羧甲基茯苓多糖（CMP）预处理人外周血淋巴细胞（HPBL），经200IU／mlIFN－α启动后，加NDV的促诱生组的α-干扰素（IFN－α）效价比无CMP的常规诱生组高1．2倍；经PHA和／或ConA促诱生组的γ-干扰素（IFN－γ）效价比无CMP的PHA和／或ConA刺激常规诱生组高0．5倍（P＜0.01），尤以CMP＋PHA＋ConA促诱生的IFN－γ效果最佳。说明CMP具有IFN－α和IFN－γ促诱生效应（P＜0．01）。用CMP促诱生的IFN－α和IFN－γ中间体经各项指标检测不仅IFN－α和IFN－γ效价高，而且可达到生物制剂药用标准，经临床试验证明安全有效。
Pretreatment of human peripheral blood lymphocytes (HPBL) with carboxymethyl tuckahoe polysaccharide (CMP) resulted in an IFN-α titer less than that of NDV-induced group after 200IU / ml IFN- CMP group was 1.2-fold higher than that of the control group. The IFN-γ titer in PHA and / or ConA-induced group was higher than that in the control group without CMP and PHA and / or ConA .5-fold (P <0.01). Especially, IFN-γ induced by CMP + PHA + ConA was the best. CMP has IFN-α and IFN-γ-induced effect (P <0.01). Induction of IFN-α and IFN-γ intermediates by CMP is not only high titer of IFN-α and IFN-γ, but also can reach the pharmaceutical standard of biological agents, which is proved to be safe and effective by clinical trials.